Results from the DELIVER and DAPA-HF Phase III trials demonstrate Dapagliflozin’ efficacy in heart failure regardless of ejection fraction
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
The SRV LHPL centre of excellence in robotic orthopaedics will be helmed by joint replacement surgeon, Dr Narendra Vaidya
New collaboration will help customers reach sustainability goals for high-performance Udel PSU polymers in demanding applications.
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
The breakthrough approval expands the existing indication of Jardiance to include adults with heart failure with preserved ejection fraction (HFpEF), an underserved patient population that previously had no approved therapies in Europe
Ten new Ayush hospitals and one Ayurvedic college will be set up in Nagaland and Mizoram
Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death or hospitalization for heart failure, regardless of ejection fraction
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
T-Charge, a next-generation platform that aims to revolutionize CAR-T cell therapy, will serve as the foundation for various investigational CAR-T therapies
Subscribe To Our Newsletter & Stay Updated
